Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults

• Váldodahkkit: Federico Martinón-Torres (Dahkki), Terry Nolan (Dahkki), Daniela Toneatto (Dahkki), Angelika Banzhoff (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2019-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

The multicomponent meningococcal serogroup B vaccine, 4CMenB, has demonstrated effectiveness in preventing invasive MenB disease in infants and in controlling MenB outbreaks. The need for/timing of additional booster doses is not yet established. We reviewed eight studies that evaluated antibody per...